{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:03:08Z","timestamp":1684468988464},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2002,11,26]],"date-time":"2002-11-26T00:00:00Z","timestamp":1038268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1038\/sj.bjc.6600660","type":"journal-article","created":{"date-parts":[[2002,11,28]],"date-time":"2002-11-28T15:44:03Z","timestamp":1038498243000},"page":"1365-1369","source":"Crossref","is-referenced-by-count":4,"title":["Block sequential adriamycin CMF \u2013 optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?"],"prefix":"10.1038","volume":"87","author":[{"given":"D A","family":"Cameron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Toy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T R J","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Le Vay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I C S","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"Grieve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T J","family":"Perren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Crown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R C F","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,11,26]]},"reference":[{"key":"BF6600660_CR1","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0140-6736(00)02841-5","volume":"356","author":"J Bergh","year":"2000","unstructured":"Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson N O, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356: 1384\u20131391","journal-title":"Lancet"},{"key":"BF6600660_CR2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","volume":"273","author":"G Bonadonna","year":"1995","unstructured":"Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. [see comments] JAMA 273: 542\u2013547","journal-title":"JAMA"},{"key":"BF6600660_CR3","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1200\/JCO.1991.9.12.2134","volume":"9","author":"R Buzzoni","year":"1991","unstructured":"Buzzoni R, Bonadonna G, Valagussa P, Zambetti M (1991) Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9: 2134\u20132140","journal-title":"J Clin Oncol"},{"key":"BF6600660_CR4","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930\u2013942","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"BF6600660_CR5","unstructured":"Early Breast Cancer Trialists Collaborative Group (2000) Unpublished Overview data for polychemotherapy for early breast cancer"},{"key":"BF6600660_CR6","first-page":"1727","volume":"63","author":"JH Goldie","year":"1979","unstructured":"Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 63: 1727\u20131733","journal-title":"Cancer Treat Rep"},{"key":"BF6600660_CR7","first-page":"439","volume":"66","author":"JH Goldie","year":"1982","unstructured":"Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439\u2013449","journal-title":"Cancer Treat Rep"},{"key":"BF6600660_CR8","first-page":"101","volume":"17","author":"IC Henderson","year":"1998","unstructured":"Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle JN, Cooper MR, Canellos G, Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level inthe adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc ASCO 17: 101 (Absract 390A)","journal-title":"Proc ASCO"},{"key":"BF6600660_CR9","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1200\/JCO.1998.16.8.2651","volume":"16","author":"MN Levine","year":"1995","unstructured":"Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenburg T, Mackenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1995) Randomized trial of intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy compared with Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women with Node-Positive Breast Cancer. J Clin Onc 16: 2651\u20132658","journal-title":"J Clin Onc"},{"key":"BF6600660_CR10","first-page":"57","volume-title":"Important advances in oncology","author":"L Norton","year":"1992","unstructured":"Norton L, Day R (eds) (1992) Potential innovations in scheduling of cancer chemotherapy. In Important advances in oncology De Vita Jr VT (ed) pp 57\u201372, Philadelphia: J.B. Lippincott"},{"key":"BF6600660_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(98)01350-6","volume":"352","author":"S Rodenhuis","year":"1998","unstructured":"Rodenhuis S, Richel DJ, Van Der Wall E, Schornagel JH, Baars JW, Konig CCE, Peterse H, Borger J, Nooijen WJ, Bakx R, Dalesio O, Rutgers E (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515\u2013521","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600660","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:46:40Z","timestamp":1684414000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,26]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["BF6600660"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600660","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,26]]}}}